Filsuvez: Dosage Form, Projected Sales, NCE-1 Date | Birch Triterpenes

Filsuvez

Filsuvez is a topical gel used on open wounds in patients with dystrophic or junctional epidermolysis bullosa (EB). It’s the first treatment that supports skin healing in this condition by promoting wound closure.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Birch Triterpenes
Innovator :

CHIESI FARMACEUTICI SPA
Approval Date :

18-Dec-23
NCE-1 Date :

18-Dec-27
NCE Date :

18-Dec-28
Dosage Form :

Topical Gel
Strength :

0.1
Therapeutic Category :

Dermatologic
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2026 :

NA
2027 :

NA
2028 :

NA
2029 :

NA
2030 :

NA
2031 :

NA
2032 :

NA

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Filsuvez

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?